EQL Pharma AB (publ)

NGM:EQL Lagerbericht

Marktkapitalisierung: SEK 1.5b

EQL Pharma Management

Management Kriterienprüfungen 1/4

EQL Pharma's CEO ist Axel Schorling , ernannt in Aug 2022, hat eine Amtszeit von 1.83 Jahren. besitzt direkt 1.07% der Aktien des Unternehmens, im Wert von SEK15.55M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.8 Jahre bzw. 5.1 Jahre.

Wichtige Informationen

Axel Schorling

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehaltsn/a
Amtszeit als Geschäftsführer1.8yrs
Eigentum des Geschäftsführers1.1%
Durchschnittliche Amtszeit des Managements1.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder5.1yrs

Jüngste Management Updates

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Recent updates

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Geschäftsführer

Axel Schorling (38 yo)

1.8yrs

Amtszeit

Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Christer Fahraeus
Founder & Chairman18.4yrsSEK 1.50mkeine Daten
Axel Schorling
President & CEO1.8yrskeine Daten1.07%
SEK 16.4m
Anna Jonsson
Chief Financial Officer2.5yrskeine Daten0.047%
SEK 722.2k
Martin Kristofferson
Chief Operating Officer1.8yrskeine Daten0.052%
SEK 799.5k
Alexander Brising
Chief Commercial Officerno datakeine Daten0.88%
SEK 13.5m
Carl Lindgren
Chief Business Development Officer1.3yrskeine Datenkeine Daten

1.8yrs

Durchschnittliche Betriebszugehörigkeit

50yo

Durchschnittliches Alter

Erfahrenes Management: EQLDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.8 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Christer Fahraeus
Founder & Chairman18.4yrsSEK 1.50mkeine Daten
Rajiv Modi
Non Independent Director9.4yrskeine Datenkeine Daten
Linda Neckmar
Independent Director4.4yrskeine Daten0.0086%
SEK 131.5k
Anders Mansson
Independent Director5.8yrskeine Daten0.034%
SEK 526.0k
Per Svangren
Independent Director3.4yrskeine Daten0.034%
SEK 526.0k
Per Ollermark
Independent Director3.4yrskeine Datenkeine Daten

5.1yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: EQLDie Vorstandsmitglieder gelten als erfahren (5.1 Jahre durchschnittliche Amtszeit).